Are you Dr. Wofsy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-502-2279Fax+1 415-502-0888
Summary
- Dr. David Wofsy, MD is a rheumatologist in San Francisco, California. He is currently licensed to practice medicine in California. He is affiliated with UCSF Medical Center, Zuckerberg San Francisco General Hospital and Trauma Center, and San Francisco VA Medical Center.
Education & Training
University of California (San Francisco)Fellowship, Rheumatology, 1983 - 1985- University of California (San Francisco)Fellowship, Rheumatology, 1977 - 1978
- University of California (San Francisco)Residency, Internal Medicine, 1974 - 1977
University of California San Diego School of MedicineClass of 1974
Certifications & Licensure
CA State Medical License 1975 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Start of enrollment: 2004 Sep 01
- Etanercept for the Treatment of Lupus Nephritis Start of enrollment: 2008 Feb 01
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Start of enrollment: 2008 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1104 citations2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus ErythematosusMartin Aringer, Karen H. Costenbader, David I. Daikh, Ralph Brinks, Marta Mosca
Arthritis & Rheumatology. 2019-09-01 - 39 citationsUrine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis.Andrea Fava, Deepak A. Rao, Chandra Mohan, Ting Zhang, Avi Z. Rosenberg
Arthritis & Rheumatology. 2021-11-16 - 95 citationsPhase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomi...Joan T. Merrill, William R Shanahan, Morton Scheinberg, Kenneth C. Kalunian, David Wofsy
Annals of the Rheumatic Diseases. 2018-03-21
Press Mentions
- Spring 2021’S Awards, Appointments & Announcements in RheumatologyMarch 15th, 2021
Lupus Research Alliance Sets Bold New Strategic Plan for Research to Accelerate Innovative Research and Treatment BreakthroughsAugust 12th, 2020
With Coronavirus Disrupting College, Should Every Student Pass?March 28th, 2020- Join now to see all
Grant Support
- Autoimmunity Center Of ExcellenceNational Institute Of Allergy And Infectious Diseases2009–2012
- UCSF Autoimmunity Center Of ExcellenceNational Institute Of Allergy And Infectious Diseases2003–2007
- Academic Rheumatology And Clinical ImmunologyNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1992–2006
- Multipurpose Arthritis And Musculoskeletal Diseases CtrNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1995–2002
- Treatment Of Rheumatic Diseases With Biologic AgentsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994
- New Strategies For Using Anti-L3t4 To Study Murine LupusNational Institute Of Allergy And Infectious Diseases1988–1990
- Feasibility Study--Monocyte Proliferation In Autoimmune BXSB MiceNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Professional Memberships
- Member
- Master Member
